

BIOMARKERS

POSTER PRESENTATION

BIOMARKERS (NON-NEUROIMAGING)

CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly

Francis Shue¹ | Launia J White¹ | Rachel Hendrix² | Jason D Ulrich³ |
Rachel L. Henson⁴ | William C. Knight⁵ | Yuka A Martens¹ | Ni Wang¹ |
Bhaskar Roy¹ | Skylar C Starling¹ | Yingxue Ren¹ | Chengjie Xiong⁶ |
Yan W. Asmann¹ | Jeremy A. Syrjanen⁷ | Maria Vassilaki⁷ | Michelle M. Mielke⁸ |
Carlos Cruchaga⁹ | David M. Holtzman⁹ | Guojun Bu¹ | Ronald C. Petersen¹⁰ |
Michael G. Heckman¹ | Takahisa Kanekiyo¹

¹Mayo Clinic, Jacksonville, FL, USA

²Washington University in St. Louis, St. Louis, MO, USA

³Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA

⁴Knight Alzheimer Disease Research Center, Saint Louis, MO, USA

⁵Washington University School of Medicine, St. Louis, MO, USA

⁶The Charles F. and Joanne Knight Alzheimer Disease Research Center, St. Louis, MO, USA

⁷Mayo Clinic, Rochester, MN, USA

⁸Wake Forest University School of Medicine, Winston-Salem, NC, USA

⁹Washington University School of Medicine, Saint Louis, MO, USA

¹⁰Department of Neurology, Mayo Clinic, Rochester, MN, USA

Correspondence

Francis Shue, Mayo Clinic, Jacksonville, FL, USA.

Email: Shue.Francis@mayo.edu

Abstract

Background: The immune system is substantially involved in the development and progression of age-related cognitive decline and Alzheimer's disease (AD).

Method: As genetic and environmental factors interactively impact these conditions, we investigated how risk factors such as APOE genotype, age, and sex influence immune activation markers and AD biomarkers in cerebrospinal fluid (CSF) in elderly individuals enrolled in the Mayo Clinic Study of Aging cohort. Among cognitively unimpaired individuals aged over 65 at the baseline visit (N=298), we measured 365 CSF immune activation markers using the proximity extension assay.

Result: We found that age, sex, and diabetes status are associated with altered CSF levels of immune activation markers independently of other factors. For CSF AD biomarkers, we observed significant positive correlations between age and total tau, phosphorylated tau-181 (p-tau181), neurofilament light (NfL), and YKL40. APOE4 was also associated with lower A β 42 and higher SNAP25 in CSF. We further examined whether baseline visit variables can predict cognitive decline, represented by the conversion from CDR=0 to CDR>0. We found that age, A β 42, NfL, and REG4 were independently correlated with CDR conversion risk. When the cohort was dichotomized by their median values, older participants with lower A β 42, higher NfL, and higher REG4 at baseline developed cognitive impairment during the follow up with a c-index of 0.762 while age alone had a c-index of 0.699.

Conclusion: Together, our results suggest that assessing CSF immune activation markers and AD biomarkers can improve the prediction of cognitive impairment risk in the elderly.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Alzheimer's Association. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.